Oncotype DX AR-V7 NUCLEUS DETECT

Publications

Clinical Validation

Several clinically validated, peer-reviewed studies illustrate the science behind the Oncotype DX AR-V7 Nucleus Detect test.

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
Scher HI, Lu D, Schreiber NA, Louw J, Graf RP; Vargas HA, Johnson A, Jendrisak A, Bambury R, Danila D, McLaughlin B, Wahl J, Greene SB, Heller G, Marrinucci D, Fleisher N, Dittamore R.
JAMA Oncol. 2016;2(11):1441-1449. doi:10.1001/jamaoncol.2016.1828

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer
Scher HI, Graf RP, Schreiber NA, McLaughlin B, Lu D, Louw J, Danila DC, Dugan L, Johnson A, Heller G, Fleisher M, Dittamore R.
Eur Urol. 2017 Jun;71(6):874-882. doi: 10.1016/j.eururo.2016.11.024.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.
N Engl J Med. 2014; 371: 1028–1038

Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer
Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.
JAMA Oncol. 2015 Aug;1(5):582-91. doi: 10.1001/jamaoncol.2015.1341.

Additional Related Articles
REFERENCES

1. Scher, HI, et al. JAMA Oncol. 2016.
2. Scher, HI, et al. Eur Urol. 2016.



a. DOI: 10.1001/jamaoncol.2016.1828
b. DOI: 10.1016/j.eururo.2016.11.024
 

Clinical Validation:
MSKa

A cross-sectional study at Memorial Sloan Kettering of 161 men with progressive mCRPC.

Read Full Text

Clinical Comparator Trialb

Investigators compared nuclear-specific and nuclear-agnostic AR-V7 testing.

Read Full Text

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™